Abstract：
BACKGROUND: Equine joint disease including septic arthritis (SA) and osteoarthritis (OA) is a critical cause of equine lameness. Platelet-rich plasma (PRP) is one of the most popular regenerative therapies to treat equine OA, even SA, but the evidence in support of the treatment is conflicting.
OBJECTIVE: The aim of the study was to systematically review the current evidence on PRP products used for SA and OA, as well as the efficacy of PRP products as treatment for OA on the basis of a meta-analysis of the available literature.
METHODS: Systematic review and meta-analysis.
METHODS: A systematic search of relevant databases (PubMed, Web of Science, Scopus) was performed to identify studies published from 2013 to 2023, in accordance with the PRISMA guidelines. Randomised controlled trials, non-randomised trials and controlled laboratory studies that used at least one type of PRP products were included. Dichotomous outcomes were presented using odds ratios (ORs) and 95% confidence intervals (95% CIs).
RESULTS: A total of 21 publications were identified in the systematic review and 5 of them in the meta-analysis. These publications involved various types of PRP products and reported different outcomes. Although most of the studies were associated with a high risk of bias, the overall estimated effect was consistent with a significant improvement in the PRP products treatment group compared with the control group (OR: 15.32; 95% CI: 3.00-78.15; p < 0.05). There was a significant improvement in clinical performance outcomes between the groups (OR: 36.64; 95% CI: 3.69-364.30; p < 0.05).
CONCLUSIONS: PRP products as intra-articular treatment are likely efficacious for treatment of equine OA and have potential for treating SA. These conclusions might be affected by the limited number of randomised controlled studies and high variability of different types of PRP products. To better evaluate the efficacy of PRP, a widely recognised classification system and the utilisation of randomised, blinded, equivalency or non-inferiority trials are required.
OBJECTIVE: The aim of the study was to systematically review the current evidence on PRP products used for SA and OA, as well as the efficacy of PRP products as treatment for OA on the basis of a meta-analysis of the available literature.
METHODS: Systematic review and meta-analysis.
METHODS: A systematic search of relevant databases (PubMed, Web of Science, Scopus) was performed to identify studies published from 2013 to 2023, in accordance with the PRISMA guidelines. Randomised controlled trials, non-randomised trials and controlled laboratory studies that used at least one type of PRP products were included. Dichotomous outcomes were presented using odds ratios (ORs) and 95% confidence intervals (95% CIs).
RESULTS: A total of 21 publications were identified in the systematic review and 5 of them in the meta-analysis. These publications involved various types of PRP products and reported different outcomes. Although most of the studies were associated with a high risk of bias, the overall estimated effect was consistent with a significant improvement in the PRP products treatment group compared with the control group (OR: 15.32; 95% CI: 3.00-78.15; p < 0.05). There was a significant improvement in clinical performance outcomes between the groups (OR: 36.64; 95% CI: 3.69-364.30; p < 0.05).
CONCLUSIONS: PRP products as intra-articular treatment are likely efficacious for treatment of equine OA and have potential for treating SA. These conclusions might be affected by the limited number of randomised controlled studies and high variability of different types of PRP products. To better evaluate the efficacy of PRP, a widely recognised classification system and the utilisation of randomised, blinded, equivalency or non-inferiority trials are required.
摘要：
背景：包括化脓性关节炎（SA）和骨关节炎（OA）的马关节病是马跛行的关键原因。富血小板血浆（PRP）是治疗马OA最流行的再生疗法之一，即使是SA,但是支持这种治疗的证据是相互矛盾的。
目的：本研究的目的是系统回顾目前关于用于SA和OA的PRP产品的证据，以及基于现有文献的荟萃分析，PRP产品治疗OA的疗效。
方法：系统评价和荟萃分析。
方法：对相关数据库的系统搜索(PubMed，WebofScience,根据PRISMA指南，进行Scopus）以确定2013年至2023年发表的研究。随机对照试验,纳入了使用至少一种PRP产品的非随机试验和对照实验室研究.使用比值比(OR)和95%置信区间(95%CIs)呈现二分结果。
结果：在系统综述中确定了21篇出版物，在荟萃分析中确定了5篇出版物。这些出版物涉及各种类型的PRP产品，并报告了不同的结果。尽管大多数研究都与高偏倚风险相关，与对照组相比,PRP产品治疗组的总体估计疗效与显著改善一致(OR:15.32;95%CI:3.00-78.15;p<0.05).两组之间的临床表现结果显着改善（OR：36.64；95％CI：3.69-364.30；p<0.05）。
结论：PRP产品作为关节内治疗可能对治疗马OA有效，并具有治疗SA的潜力。这些结论可能会受到有限数量的随机对照研究和不同类型PRP产品的高变异性的影响。为了更好地评价PRP的疗效，广泛认可的分类系统和随机化的利用，失明,需要进行等效或非劣性试验。
目的：本研究的目的是系统回顾目前关于用于SA和OA的PRP产品的证据，以及基于现有文献的荟萃分析，PRP产品治疗OA的疗效。
方法：系统评价和荟萃分析。
方法：对相关数据库的系统搜索(PubMed，WebofScience,根据PRISMA指南，进行Scopus）以确定2013年至2023年发表的研究。随机对照试验,纳入了使用至少一种PRP产品的非随机试验和对照实验室研究.使用比值比(OR)和95%置信区间(95%CIs)呈现二分结果。
结果：在系统综述中确定了21篇出版物，在荟萃分析中确定了5篇出版物。这些出版物涉及各种类型的PRP产品，并报告了不同的结果。尽管大多数研究都与高偏倚风险相关，与对照组相比,PRP产品治疗组的总体估计疗效与显著改善一致(OR:15.32;95%CI:3.00-78.15;p<0.05).两组之间的临床表现结果显着改善（OR：36.64；95％CI：3.69-364.30；p<0.05）。
结论：PRP产品作为关节内治疗可能对治疗马OA有效，并具有治疗SA的潜力。这些结论可能会受到有限数量的随机对照研究和不同类型PRP产品的高变异性的影响。为了更好地评价PRP的疗效，广泛认可的分类系统和随机化的利用，失明,需要进行等效或非劣性试验。
